A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma
Academic Article
Overview
MeSH Major
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Papillary
Carcinoma, Renal Cell
Kidney Neoplasms
abstract
BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.
